SD231103-068 page 1 of 1

PharmLabs San Diego Certificate of Analysis

3421 Hancock St, Second Floor, San Diego, CA 92110 | License: C8-0000098-LIC ISO/IEC 17025:2017 Acc. L17-427-1 #85368

Received Nov 03, 2023

Sample PAPAYA PUNCH - DIAMOND SAUCE 5g

Sample ID SD231103-068 (86948) Matrix Concentrate (Inhalable Cannabis Good)

Tested for Latro inc Sampled -Analyses executed CANX

Laboratory note: The estimated concentration of the unknown peak in this sample is 2.17%. Currently, PharmLabs laboratory can not confirm the unidentified peak in your chromatogram due to an interference (only with concentrated d8 products) from which we believe to be an isomer of d8-THC or d9-THC. The U peak totals will not be included in the cannobinoid totals at the bottom of the potencu section.


Reported Nov 06, 2023

Unit Mass (g) 5.0

CANX - Cannabinoids Analysis

Analyzed Nov 06, 2023 | Instrument HPLC-VWD | Method SOP-001

The expanded Uncertainty of the Cannabinoid analysis is approximately #.806% at the 95% Confidence Level LOD LOQ Result mg/g mg/g % Result mg/g Result mg/Unit Analyte 11-Hydroxy- Δ 8-Tetrahydrocannabivarin (11-Hyd- Δ 8-THCV) 0.013 0.041 ND ND ND Cannabidiorcin (CBDO) 0.002 0.007 ND ND ND Abnormal Cannabidiorcin (a-CBDO) 0.01 0.031 ND ND ND (+/-)-9B-hydroxy-Hexahydrocannibinol (9b-HHC) 0.012 0.036 ND ND ND 11-Hydroxy- Δ 8-Tetrahydrocannabinol (11-Hyd- Δ 8-THC) 0.007 0.021 ND ND ND Cannabidiolic Acid (CBDA) 0.001 0.16 ND ND ND Cannabiaerol Acid (CBGA) 0.001 0.16 ND ND ND Cannabigerol (CBG) 0.001 0.16 5.97 59.66 298.30 Cannabidiol (CBD) 0.001 0.16 1(S)-THD (s-THD) 0.013 0.041 ND ND ND 1(R)-THD (r-THD) 0.025 0.075 ND ND ND Tetrahydrocannabivarin (THCV) 0.001 0.16 ND ND ND Δ8-tetrahydrocannabivarin (Δ8-THCV) 0.021 0.064 ND ND ND Cannabidihexol (CBDH) 0.005 0.16 ND ND ND Tetrahydrocannabutol (Δ9-THCB) 0.013 0.038 ND ND ND Cannabinol (CBN) 0.001 0.16 0.08 0.82 4.10 Cannabidiphorol (CBDP) 0.015 0.047 ND ND ND exo-THC (exo-THC) 0.005 0.16 ND ND ND Tetrahydrocannabinol (Δ9-THC) 0.003 0.16 U UI UI Δ 8-tetrahydrocannabinol (Δ 8-THC) 0.004 0.16 7.17 71.68 358 40 (6aR,9S)-∆10-Tetrahydrocannabinol ((6aR,9S)-∆10) 0.015 0.16 2.21 22.07 110.35 Hexahydrocannabinol (S Isomer) (9s-HHC) 0.017 0.16 9 58 95.81 479.05 (6aR,9R)- Δ 10-Tetrahydrocannabinol ((6aR,9R)- Δ 10) 0.007 0.16 22.82 228.21 1141.05 Hexahydrocannabinol (R Isomer) (9r-HHC) 0.016 0.16 14.39 143 87 719.35 Tetrahydrocannabinolic Acid (THCA) 0.001 0.16 ND ND ND $\Delta 9$ -Tetrahydrocannabihexol ($\Delta 9$ -THCH) 0.024 0.071 ND ND ND Cannabinol Acetate (CBNO) 0.014 0.043 ND ND ND $\Delta 9$ -Tetrahydrocannabiphorol ($\Delta 9$ -THCP) 0.017 0.16 16.88 168.81 844.05 Δ8-Tetrahydrocannabiphorol (Δ8-THCP) 0.041 0.16 0.90 8.99 44.95 Cannabicitran (CBT) 0.005 0.16 3.70 37.02 185.10 Δ 8-THC-O-acetate (Δ 8-THCO) 0.076 0.16 ND ND ND 9(S)-HHCP (s-HHCP) 0.031 0.094 ND ND ND 0.066 0.16 Δ9-THC-O-acetate (Δ9-THCO) ND ND ND 9(R)-HHCP (r-HHCP) 0.026 0.079 ND ND ND 9(S)-HHC-O-acetate (s-HHCO) 0.005 0.16 ND ND ND 9(R)-HHC-O-acetate (r-HHCO) 0.008 0.025 ND ND ND 3-octyl-∆8-Tetrahydrocannabinol (∆8-THC-C8) 0.067 0.204 ND ND ND Total THC (THCa * 0.877 + A9THC) UI UI UI Total THC + Δ 8THC + Δ 10THC (THCa * 0.877 + Δ 9THC + Δ 8THC + Δ 10THC) 32.20 321.96 1609.80 Total CBD (CBDa * 0.877 + CBD) ND ND ND Total CBG (CBGa * 0.877 + CBG) 5.97 59.66 298.30 23.97 239.68 Total HHC (9r-HHC + 9s-HHC) 1198.40 Total Cannabinoids 83.69 836.94 4184.70



UI Unidentified ND Not Detected N/A Not Applicable NT Not Reported LOD Limit of Detection LOQ Limit of Quantification <LOQ Detected >ULOL Above upper limit of UL/A Come Determine Linki <LOQ Detected >ULOL Above upper limit of linearity CFU/g Colony Forming Units per 1 gram TNTC Too Numerous to Count





Authorized Signature

Brandon Starr

Brandon Starr, Lab Manager 10n, 06 Nov 2023 12:27:04 -0800

Scan th

PharmLabs San Diego | 3421 Hancock St, Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Acc. L17-427-1 This report shall not be reprodued except in full, without the written approval of the Job. This report is for informational purposes only and should not be used to diagnose, treat or prevent any disease. Results are enabled to be proceeding to the processing and should not be used to diagnose. The use of the use the should not be included in the proceeding to the processing and should not be used to be proceeding to the processing and should not be used to be proceeding to the use and be the included in the proceeding to the proceeding to the processing to the pr

QA Testing



